JP4303303B2 - Ｅｍｌ４−ａｌｋ融合遺伝子 - Google Patents

Ｅｍｌ４−ａｌｋ融合遺伝子 Download PDF

Info

Publication number
JP4303303B2
JP4303303B2 JP2007265917A JP2007265917A JP4303303B2 JP 4303303 B2 JP4303303 B2 JP 4303303B2 JP 2007265917 A JP2007265917 A JP 2007265917A JP 2007265917 A JP2007265917 A JP 2007265917A JP 4303303 B2 JP4303303 B2 JP 4303303B2
Authority
JP
Japan
Prior art keywords
seq
polypeptide
eml4
polynucleotide
alk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2007265917A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008295444A (ja
JP2008295444A5 (enExample
Inventor
博行 間野
貞夫 黒光
信昭 新堂
孝利 曽我
崇 古谷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Curegene
Original Assignee
Curegene
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curegene filed Critical Curegene
Priority to JP2007265917A priority Critical patent/JP4303303B2/ja
Priority to US12/100,595 priority patent/US7605131B2/en
Publication of JP2008295444A publication Critical patent/JP2008295444A/ja
Publication of JP2008295444A5 publication Critical patent/JP2008295444A5/ja
Application granted granted Critical
Publication of JP4303303B2 publication Critical patent/JP4303303B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2007265917A 2006-10-11 2007-10-11 Ｅｍｌ４−ａｌｋ融合遺伝子 Active JP4303303B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2007265917A JP4303303B2 (ja) 2006-10-11 2007-10-11 Ｅｍｌ４−ａｌｋ融合遺伝子
US12/100,595 US7605131B2 (en) 2006-10-11 2008-04-10 EML4-ALK fusion gene

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2006277718 2006-10-11
JP2007120670 2007-05-01
CA 2598893 CA2598893C (en) 2006-10-11 2007-08-24 Eml4-alk fusion gene
JP2007265917A JP4303303B2 (ja) 2006-10-11 2007-10-11 Ｅｍｌ４−ａｌｋ融合遺伝子

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009035918A Division JP5172736B2 (ja) 2006-10-11 2009-02-18 Ｅｍｌ４−ａｌｋ融合遺伝子

Publications (3)

Publication Number Publication Date
JP2008295444A JP2008295444A (ja) 2008-12-11
JP2008295444A5 JP2008295444A5 (enExample) 2009-02-12
JP4303303B2 true JP4303303B2 (ja) 2009-07-29

Family

ID=39277176

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007265917A Active JP4303303B2 (ja) 2006-10-11 2007-10-11 Ｅｍｌ４−ａｌｋ融合遺伝子
JP2009035918A Active JP5172736B2 (ja) 2006-10-11 2009-02-18 Ｅｍｌ４−ａｌｋ融合遺伝子

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009035918A Active JP5172736B2 (ja) 2006-10-11 2009-02-18 Ｅｍｌ４−ａｌｋ融合遺伝子

Country Status (7)

Country Link
US (7) US7728120B2 (enExample)
EP (1) EP2116553B1 (enExample)
JP (2) JP4303303B2 (enExample)
AT (1) ATE450547T1 (enExample)
CA (1) CA2598893C (enExample)
DE (1) DE602007003543D1 (enExample)
ES (2) ES2335368T3 (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012029577A1 (ja) 2010-09-02 2012-03-08 学校法人 久留米大学 単分子dnaから形成される環状dnaの作成方法
WO2013031700A1 (ja) 2011-08-31 2013-03-07 学校法人 久留米大学 Dna分子の環状化において単分子による環状化dnaのみを選別する方法
WO2015111716A1 (ja) 2014-01-24 2015-07-30 公益財団法人がん研究会 新規融合体及びその検出法
EP2990493A1 (en) 2014-09-01 2016-03-02 ARKRAY, Inc. Primer reagent for amplifying alk fusion gene, alk fusion gene amplification reagent kit including the same, and alk fusion gene amplification method and alk fusion gene analysis method using the same
US10705087B2 (en) 2013-07-26 2020-07-07 Japanese Foundation For Cancer Research Detection method for NTRK3 fusion
US10921311B2 (en) 2016-01-15 2021-02-16 Japanese Foundation For Cancer Research Fusions and method for detecting same

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120208824A1 (en) 2006-01-20 2012-08-16 Cell Signaling Technology, Inc. ROS Kinase in Lung Cancer
US7700339B2 (en) * 2006-04-14 2010-04-20 Cell Signaling Technology, Inc. Gene defects and mutant ALK kinase in human solid tumors
US8168383B2 (en) 2006-04-14 2012-05-01 Cell Signaling Technology, Inc. Gene defects and mutant ALK kinase in human solid tumors
EP2016089B1 (en) * 2006-04-14 2014-01-15 Cell Signaling Technology, Inc. Gene defects and mutant alk kinase in human solid tumors
CA2598893C (en) * 2006-10-11 2012-04-10 Astellas Pharma Inc. Eml4-alk fusion gene
TWI389893B (zh) * 2007-07-06 2013-03-21 Astellas Pharma Inc 二（芳胺基）芳基化合物
JP2011511949A (ja) * 2008-02-12 2011-04-14 ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド 肺癌におけるｅｍｌ４とａｌｋの融合のためのｆｉｓｈアッセイ
JP2009219728A (ja) * 2008-03-18 2009-10-01 Daito Giken:Kk 遊技台
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
AU2009248923B2 (en) 2008-05-21 2015-01-29 Takeda Pharmaceutical Company Limited Phosphorous derivatives as kinase inhibitors
JP2012526563A (ja) * 2009-05-15 2012-11-01 インサイト ジェネティクス インコーポレイテッド 癌を診断および治療するためのａｌｋの融合に関する方法および組成物
EP2487250A4 (en) 2009-10-06 2013-03-20 Fujirebio Kk METHOD FOR DETECTING FUSION GENES
US9175350B2 (en) * 2009-12-22 2015-11-03 Quest Diagnostics Investments Incorporated EML4-ALK translocations in lung cancer
WO2011102507A1 (ja) 2010-02-22 2011-08-25 富士レビオ株式会社 癌遺伝子の同定方法、癌遺伝子発現細胞の樹立方法、および癌遺伝子標的薬のスクリーニング方法
US8383793B2 (en) 2010-04-15 2013-02-26 St. Jude Children's Research Hospital Methods and compositions for the diagnosis and treatment of cancer resistant to anaplastic lymphoma kinase (ALK) kinase inhibitors
AR080913A1 (es) * 2010-04-16 2012-05-16 Response Genetics Cebadores, sondas, metodos y conjuntos de elementos para la deteccion de variantes de eml4- alk
WO2012019132A2 (en) 2010-08-06 2012-02-09 Cell Signaling Technology, Inc. Anaplastic lymphoma kinase in kidney cancer
CN103052386B (zh) 2010-08-20 2016-03-02 中外制药株式会社 含有四环化合物的组合物
JP2014005206A (ja) * 2010-10-22 2014-01-16 Astellas Pharma Inc アリールアミノヘテロ環カルボキサミド化合物
JP5769952B2 (ja) * 2010-11-12 2015-08-26 株式会社Ｌｓｉメディエンス Ｅｍｌ４−ａｌｋ融合遺伝子の高感度検出方法
WO2012075318A2 (en) * 2010-12-01 2012-06-07 Cell Signaling Technology, Inc. Fn1 and alk gene translocations in cancer and alk kinase expression in ovarian cancer
DK2670401T3 (en) * 2011-02-02 2015-09-07 Novartis Ag Methods for using the ALK-inhibitors
US20140296181A1 (en) * 2011-04-07 2014-10-02 Coferon, Inc. Methods of modulating oncogenic fusion proteins
US9834518B2 (en) 2011-05-04 2017-12-05 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in EGFR-driven cancers
DK2838998T3 (en) 2012-04-18 2018-01-15 Cell Signaling Technology Inc EGFR AND ROS1 IN CANCER
JP6469567B2 (ja) 2012-05-05 2019-02-13 アリアド・ファーマシューティカルズ・インコーポレイテッド Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物
US9084456B1 (en) * 2012-05-28 2015-07-21 Jack Zemer Linkage for jewelry components
EP2892536B1 (en) 2012-09-06 2019-12-18 Epizyme, Inc. Method of treating leukemia
JP2016510316A (ja) * 2012-12-21 2016-04-07 エピザイム，インコーポレイティド 白血病の治療に使用するためのｄｏｔ１ｌ阻害剤
MX2015010791A (es) 2013-02-22 2015-11-26 Hoffmann La Roche Metodos para tratar el cancer y prevenir la resistencia a farmacos.
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
JPWO2015064621A1 (ja) * 2013-10-29 2017-03-09 公益財団法人がん研究会 新規融合体及びその検出法
WO2015064620A1 (ja) * 2013-10-29 2015-05-07 公益財団法人がん研究会 新規融合体及びその検出法
CN106458967A (zh) 2014-04-25 2017-02-22 中外制药株式会社 四环化合物的新结晶
EP4397659A3 (en) 2014-04-25 2024-10-02 Chugai Seiyaku Kabushiki Kaisha Preparation containing tetracyclic compound at high dose
TWI718102B (zh) 2014-08-08 2021-02-11 日商中外製藥股份有限公司 ４環性化合物的非晶質體
JP6740172B2 (ja) * 2017-05-02 2020-08-12 セル・シグナリング・テクノロジー・インコーポレイテツド ヒト固形腫瘍における遺伝子欠失及び突然変異ａｌｋキナーゼ
WO2020006314A1 (en) * 2018-06-27 2020-01-02 City Of Hope Modification of small rnas for therapeutic uses
MX2020014262A (es) 2018-06-29 2021-03-25 Chugai Pharmaceutical Co Ltd Composicion farmaceutica que comprende un agente basico poco soluble.
JP7385191B2 (ja) * 2019-08-30 2023-11-22 学校法人同志社 Ｅｍｌ４－ａｌｋ阻害ペプチドおよびこれを含む肺がん治療薬
JP2020156481A (ja) * 2020-04-06 2020-10-01 セル・シグナリング・テクノロジー・インコーポレイテツド ヒト固形腫瘍における遺伝子欠失及び突然変異ａｌｋキナーゼ
CN118159274A (zh) 2021-10-28 2024-06-07 中外制药株式会社 糖浆剂
IL317839A (en) 2022-07-04 2025-02-01 Chugai Pharmaceutical Co Ltd Combination drug
JPWO2024048555A1 (enExample) 2022-08-30 2024-03-07

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60043783D1 (de) 1999-11-11 2010-03-18 Astellas Pharma Inc Metalloprotease mit aggrecanase-aktivität
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
AU2004259012C1 (en) 2003-07-23 2012-08-02 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
PL2287156T3 (pl) 2003-08-15 2013-11-29 Novartis Ag 2,4-Di(fenyloamino)-pirymidyny stosowane w leczeniu chorób nowotworowych, chorób zapalnych i zaburzeń układu immunologicznego
JP2008502595A (ja) 2004-03-31 2008-01-31 エグゼリクシス， インコーポレイテッド 未分化リンパ腫キナーゼモジュレータおよびその使用方法
EP2016089B1 (en) 2006-04-14 2014-01-15 Cell Signaling Technology, Inc. Gene defects and mutant alk kinase in human solid tumors
CA2598893C (en) * 2006-10-11 2012-04-10 Astellas Pharma Inc. Eml4-alk fusion gene
TWI389893B (zh) 2007-07-06 2013-03-21 Astellas Pharma Inc 二（芳胺基）芳基化合物

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012029577A1 (ja) 2010-09-02 2012-03-08 学校法人 久留米大学 単分子dnaから形成される環状dnaの作成方法
WO2013031700A1 (ja) 2011-08-31 2013-03-07 学校法人 久留米大学 Dna分子の環状化において単分子による環状化dnaのみを選別する方法
US10705087B2 (en) 2013-07-26 2020-07-07 Japanese Foundation For Cancer Research Detection method for NTRK3 fusion
WO2015111716A1 (ja) 2014-01-24 2015-07-30 公益財団法人がん研究会 新規融合体及びその検出法
US10048277B2 (en) 2014-01-24 2018-08-14 Japanese Foundation For Cancer Research Method for detecting an FGFR3/TACC3 fusion protein, or encoding gene thereof
EP2990493A1 (en) 2014-09-01 2016-03-02 ARKRAY, Inc. Primer reagent for amplifying alk fusion gene, alk fusion gene amplification reagent kit including the same, and alk fusion gene amplification method and alk fusion gene analysis method using the same
US10597725B2 (en) 2014-09-01 2020-03-24 Arkray, Inc. Primer reagent for amplifying ALK fusion gene, ALK fusion gene amplification reagent kit including the same, and ALK fusion gene amplification method and ALK fusion gene analysis method using the same
US10921311B2 (en) 2016-01-15 2021-02-16 Japanese Foundation For Cancer Research Fusions and method for detecting same

Also Published As

Publication number Publication date
US7964710B2 (en) 2011-06-21
US20110230545A1 (en) 2011-09-22
JP2008295444A (ja) 2008-12-11
ES2335368T3 (es) 2010-03-25
CA2598893A1 (en) 2008-04-11
US9932589B2 (en) 2018-04-03
EP2116553A1 (en) 2009-11-11
US20100240673A1 (en) 2010-09-23
US9029521B2 (en) 2015-05-12
JP2009100783A (ja) 2009-05-14
JP5172736B2 (ja) 2013-03-27
DE602007003543D1 (de) 2010-01-14
US20080090776A1 (en) 2008-04-17
US7728120B2 (en) 2010-06-01
US20150184161A1 (en) 2015-07-02
US7605131B2 (en) 2009-10-20
EP2116553B1 (en) 2014-07-30
US8197818B2 (en) 2012-06-12
CA2598893C (en) 2012-04-10
US20130158095A1 (en) 2013-06-20
ATE450547T1 (de) 2009-12-15
US20180066266A1 (en) 2018-03-08
ES2515170T3 (es) 2014-10-29
US20090099193A1 (en) 2009-04-16

Similar Documents

Publication Publication Date Title
JP4303303B2 (ja) Ｅｍｌ４−ａｌｋ融合遺伝子
EP1914240B1 (en) EML4-ALK fusion gene
AU2020202555B2 (en) Novel fusion molecules and uses thereof
JP6493681B2 (ja) 肺がんで見出された新規融合遺伝子
US10004739B2 (en) Methods for treating cancer by inhibiting FGFR3/TACC3 fusion protein
EP3072964A1 (en) Novel chimera gene atf7ip-pdgfrb for acute lymphoblastic leukemia
WO2015066452A2 (en) Methods of treating pediatric cancers
EP3085781A1 (en) Novel fusion gene as factor responsible for stomach cancer
KR102406334B1 (ko) Nras-돌연변이 암의 치료에서 사용하기 위한 egfr 억제제 및 mek 억제제의 조합물
WO2022244807A1 (ja) Ｌｔｋ融合遺伝子
JP2014054185A (ja) 新規ｂｒａｆ融合体の検出法
JPWO2015064620A1 (ja) 新規融合体及びその検出法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081219

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20081219

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20081219

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20090115

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090312

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20090407

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20090423

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120501

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

Ref document number: 4303303

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130501

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130501

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140501

Year of fee payment: 5

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140501

Year of fee payment: 5

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250